BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Nov 08, 2010
 |  BC Week In Review  |  Company News  |  Other News

Stallergenes, Ares Life Sciences, Wendel inflammation news

Fellow investment firm Ares proposed to acquire Wendel's 45.87% interest in Stallergenes for €358.8 million ($501.3 million), or €59 per share. The price is a 9% discount to Stallergenes' close of €64.50 on Oct. 28...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >